Meeting
2022 ASCO Quality Care Symposium
Adjuvant treatment decisions among women age > 65 with early-stage, hormone-receptor breast cancer seen in multidisciplinary clinic versus standard consultation.
Authors
Sara Rachel Alcorn
The Johns Hopkins Hospital, Baltimore, MD
Sara Rachel Alcorn, Keara English, Mary Wilkinson, Karen L. Smith, Raquel Nunes, Kelly Tadken, Jennie Tarica, Hanh-Tam Tran, Maureen O'Donnell, Jean L Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Integrating Patient Experience Assessment and Patient Reported Outcomes Into Practice
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 281)
DOI
10.1200/JCO.2022.40.28_suppl.281
Abstract #
281
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
First Author: Tara Beth Sanft
First Author: Jenny Wei
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
First Author: Adam Brufsky